knowledge -WSS

knowledge

author：explore 2025-10-01 00:07:18 - browse：1

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： What to know about a major upcoming Wegovy heart health study

WSS

Montana youths win climate lawsuit against state for promoting fossil fuels

Novo Nordisk touts Wegovy study, but still struggling with supply

Dozens dead from Maui wildfires: What we know about the victims

Montana youths win climate lawsuit against state for promoting fossil fuels

After Optum profits sink, UnitedHealth makes changes

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

explore

knowledge

focus

Peter Hotez and the public health issue of online harassment

With fresh data, a dynamic duo powers Eli Lilly to new heights

Affirmative action in medical school literally saved lives

BMS, looking to build heart drug business, turns to AI for diagnosis

DIEP, the 'gold standard' of breast reconstruction, is under threat

Sen. Bill Cassidy on how to lower drug prices

Moonlake's readout produced a cash windfall. Risks remain

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Supreme Court strikes down use of affirmative action

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

leisure time

How corporate America is slashing DEI workers amid backlash to diversity programs

With fresh data, a dynamic duo powers Eli Lilly to new heights

The PBM ad wars are taking over Washington, D.C.

Sen. Bill Cassidy on how to lower drug prices

Maui wildfire now ranks as the fifth

After Optum profits sink, UnitedHealth makes changes

leisure time

hotspot

hotspot

entertainment